Quick Facts

• Management of chronic alcoholism
• Used as an aid to manage alcohol dependence

---

Улькавис: Main Uses and Benefits

Улькавис (Disulfiram) is a medication used in the management of chronic alcoholism. It is administered to provide support for patients who wish to remain in a state of enforced sobriety, allowing them to avoid the consumption of alcohol.

This medication is not a cure for alcohol dependence but serves as an important component of a comprehensive treatment program that typically includes counseling and psychological support. The mechanism of action is based on the drug's effect when alcohol is ingested, which produces an acute and unpleasant physical reaction.

The primary therapeutic benefit of using this agent is to help maintain alcohol abstinence. It is indicated for individuals who are able to be managed under close medical supervision and who are committed to this form of supportive therapy for their alcohol dependence.

Who Can and Cannot Use Улькавис? (Bismuthate Tripotassium Dicitrate)

The eligibility to use Улькавис is defined strictly by regulatory authorities, with specific contraindications and age-based limitations.

---

Contraindicated Populations (Must Not Use)

• Pregnancy and Lactation: Use is absolutely contraindicated during both pregnancy and breastfeeding .
• Severe Renal Impairment: The medicine is strictly prohibited for patients with severe kidney failure (severe renal impairment) due to the risk of bismuth accumulation.
• Hypersensitivity: Individuals with known allergy to Bismuthate Tripotassium Dicitrate or any component of the formulation.

---

Age-Based and Conditional Eligibility

Population Group	Regulatory Status
Children under 4 years	Contraindicated. Not approved for use in infants or toddlers.
Children 4 to 18 years	Use not established. Safety and efficacy data are often deemed insufficient by regulatory bodies across this range.
Adults	Allowed. Permitted for use under standard labeled conditions.

---

Eligibility Constraints

The medicine is not recommended for prolonged administration exceeding the labeled duration (typically two months) or for use concurrently with other bismuth-containing products. Official documentation advises caution for patients with a history of liver disease, although hepatic impairment is not an absolute contraindication.

Interactions with other medicines and products

The official regulatory profile for Улькавис (Disulfiram) defines specific, clinically significant interactions requiring strict adherence to documented restrictions found in government prescribing information.

Contraindicated Combinations

Co-administration with several substances is formally prohibited in regulatory documentation:

• Alcohol (Ethanol): All forms of alcohol, including alcohol-containing products (e.g., mouthwashes, sauces, cough syrups), are contraindicated due to the risk of the severe Disulfiram-alcohol reaction. This restriction requires a mandatory 12-hour abstinence from alcohol before beginning treatment, and avoidance for at least 14 days after discontinuation.
• Metronidazole and Paraldehyde are also listed as prohibited combinations due to the risk of acute psychoses and confusion.

Pharmacokinetic and Exposure Effects

Улькавис is documented to inhibit the hepatic metabolism of several co-administered medicines. This pharmacokinetic interaction reduces the clearance rate of the interacting drug, resulting in increased plasma concentration and the potential for greater exposure or toxicity.

• Phenytoin and its congeners: Co-administration may lead to Phenytoin intoxication due to increased serum levels.
• Oral Anticoagulants (e.g., Warfarin): The drug may prolong prothrombin time by inhibiting their metabolism.
• Tricyclic Antidepressants and certain Benzodiazepines also face reduced clearance, leading to elevated exposure.
• Isoniazid requires monitoring for unsteady gait or marked mental status changes when used concurrently, based on pharmacodynamic concerns noted in official labels.

The interaction risk may be amplified in patients with decreased hepatic function, a consideration noted in regulatory documents regarding concomitant therapy.

The biological action of Bismuth Tripotassium Dicitrate involves multiple mechanistic domains, primarily characterized by local surface interactions and enzyme inhibition within the upper gastrointestinal tract.

Local Bismuth-Protein Barrier Formation

This mechanism centers on the physical binding and coating of tissue. Upon contact with stomach acid, the active ingredient precipitates and adheres selectively to proteins exposed at the site of mucosal damage, forming a stable, insulating layer. This action provides a shield against the corrosive effects of gastric acid and the digestive enzyme pepsin, limiting chemical exposure to the underlying epithelial tissue.

boldsymbolH. pylori Enzyme Inhibition

Улькавис exerts a local antimicrobial effect by targeting the essential survival systems of the bacterium Helicobacter pylori. The bismuth cation ( Bi^3+) is absorbed by the bacteria, where it acts as an inhibitor for critical enzymes, including urease and catalase. This interference disrupts bacterial metabolism and integrity, resulting in the modulation of the H. pylori population.

Modulation of Mucosal Defense Factors

This domain involves the drug acting as a local modulator that affects the intrinsic defense systems of the gastrointestinal lining. The drug is associated with increased synthesis and release of prostaglandin E2 ( PGE2) and bicarbonate ( HCO3^-) ions. PGE2 affects local blood flow and mucus quality, while bicarbonate helps neutralize acid at the mucosal surface, which promotes cell viability and structural stabilization at the mucosal surface.

Official Administration Guidelines

Улькавис (Bismuthate Tripotassium Dicitrate) is approved for peroral (oral) administration, supplied as a film-coated tablet or as a component in a fixed-dose combination capsule. The administration protocol is defined to ensure the drug's localized protective action in the gastrointestinal tract.

---

Standard Labeled Dosing

Treatment regimens are based on the condition being addressed, but must not exceed the equivalent of approximately 480 mg of Bi2O3 per day. For general ulcer treatment, two main schedules are detailed: one dose four times daily (q.i.d.) or two doses taken twice daily (b.i.d.). The ulcer treatment course typically lasts between four and eight weeks, with the maximum duration of use restricted to two months. For H. pylori eradication, the combination regimen is prescribed for a non-adjustable 10 day course.

---

Preparation and Administration Specifics

Instruction Entity	Guideline
Timing in relation to meals	Dosing should occur after meals and at bedtime (for combination therapy) or 30 minutes before main meals (for monotherapy), depending on the regimen.
In-Take Method	Tablets must be swallowed whole with a sufficient amount of water.
Special Restrictions	Users must strictly avoid taking antacids, milk/dairy products, or any other bismuth-containing product concurrently.

---

Population-Specific Use

Administration is generally restricted based on systemic exposure potential. For instance, the safety and efficacy of the drug are not established in pediatric patients, and use is contraindicated in patients with severe renal impairment.

Research Evidence / Overview of Studies for Улькавис

Evidence Supporting the Use in H. pylori Infection and Ulcer Healing

This research area has been investigated primarily through Randomized Controlled Trials (RCTs) and meta-analyses that explored outcomes related to the healing of gastric and duodenal ulcers. Studies evaluated the agent as a component within a multiple-drug regimen, such as quadruple therapy. The outcomes that researchers monitored included measurements related to infection status and the rate of ulcer healing as assessed through endoscopic procedures.

What remains uncertain is the agent's isolated contribution to these measured outcomes. Because the drug was always studied as one of four components in a regimen, the evidence is complex and does not clearly determine the precise role of the drug when used alone. Data for long-term outcomes related to ulcer status maintenance years later are not fully established.

---

Evidence Supporting the Use in Maintaining Alcohol Abstinence

Clinical research has focused on adults with conditions associated with Alcohol Use Disorder. Studies, primarily RCTs, evaluated the agent's administration as supportive therapy. The outcomes that researchers monitored included measurements of alcohol consumption status and the time elapsed to a consumption event (lapse or relapse).

Trials reported how patient outcomes evolved, with patterns observed in patients receiving treatment under direct supervision. When patients were studied in unsupervised settings, findings were mixed, and data indicated high variability in outcomes. This is a key limitation, as results heavily rely on compliance protocols. Follow-up durations were limited, with most high-quality research focusing on intermediate-term observation periods of six months to one year.

---

Key Limitations and Areas of Uncertainty in the Research

For both clinical contexts, the overall evidence landscape presents a few key limitations. The research provides context but not individual predictions, and the study results reflect the specific conditions under which they were conducted. Data for certain groups, such as children and older adults with complex comorbidities, remain insufficient.

Common questions about Улькавис (FAQ)

Q: Can I take it for a migraine?

Official product information states that this medicine is indicated for the temporary relief of mild to moderate pain, which includes symptoms of headache and migraine. The specific indications, such as migraine relief, are typically listed on the packaging or in the patient information leaflet for the relevant product formulation.

Q: Is it safe to use for long periods (e.g., 6 months or more)?

The official regulatory documents indicate that this product is generally intended for short-term use only. Taking the medicine for longer than directed or in higher doses may increase the risk of serious side effects. These risks, associated with long-term use, can include cardiovascular issues (such as heart attack or stroke) and serious gastrointestinal bleeding. Consultation with a healthcare professional is recommended for managing chronic or long-term pain.

Q: Can children 2 years old use it?

The suitability for children depends heavily on the specific formulation. Some liquid or suspension forms of the medicine may be used for children as young as 6 months (or 3 months in the UK), typically dosed based on body weight. However, regulatory warnings often state that oral tablets may be contraindicated (should not be used) in children younger than 6 years of age or those below 20 kg body weight. For children under 12, a healthcare professional is best suited to determine the appropriate use and dose based on the child's specific condition and weight.

Official Storage and Disposal Requirements

The storage and disposal instructions for Улькавис (Bismuthate Tripotassium Dicitrate) tablets are strictly defined in regulatory labeling to maintain product stability and ensure proper handling.

Requirement Category	Official Instruction
Temperature	Store at a temperature not exceeding 25 C.
Protection	Keep protected from moisture and avoid freezing.
Packaging	Must remain in the original container/package until the time of use.
Child Safety	Keep out of the sight and reach of children.

Proper disposal of unused or expired tablets is governed by environmental regulations. The product must be discarded according to local requirements and must not be disposed of via wastewater or routine household trash.